HJB and MabSpace Merge to Combine Bioprocessing and mAb Discovery Skills
publication date: Jan 2, 2019
HJB, a China based-bioprocessing specialist, will merge with MabSpace of Suzhou, a discovery/development biotech, to form Transcenta Holding. The new company will have a pipeline of 10 innovative molecules. It plans to use HJB's capabilities to shorten the timeline from target to BLA, using its next-gen Hangzhou GMP facility to support development of in-house and partnered molecules. Dr. Xueming Qian, former MabSpace Founder, Chairman and CEO, will be CEO of Transcenta, while Dr. Jonathan Yining Zhao, Co-founder and CEO of HJB, will be its Executive Chairman. Financial details were not disclosed. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.